PMID- 35752874
OWN - NLM
STAT- MEDLINE
DCOM- 20221019
LR  - 20230317
IS  - 1879-1190 (Electronic)
IS  - 1072-7515 (Linking)
VI  - 235
IP  - 5
DP  - 2022 Nov 1
TI  - Comparison Between Sporadic and Multiple Endocrine Neoplasia Type 1-Associated 
      Insulinoma.
PG  - 756-763
LID - 10.1097/XCS.0000000000000307 [doi]
AB  - BACKGROUND: The differences between sporadic and multiple endocrine neoplasia 
      type 1 (MEN-1)-associated insulinoma are not well described. Herein, we compared 
      demographics, neoplasm characteristics, presentation, and survival in patients 
      with sporadic vs MEN-1 insulinomas including benign and malignant disease. STUDY 
      DESIGN: A retrospective study identified insulinoma patients. MEN-1 was defined 
      based on genetic testing or clinically in patients with 2 or more primary MEN-1 
      tumor types. RESULTS: A total of 311 patients were identified: 84% benign and 16% 
      malignant. The incidence of malignancy was similar (18% vs 16%, MEN-1 vs 
      sporadic, p = 0.76). Within malignant patients, the median (interquartile range) 
      age was 33 (25 ,44) years in MEN-1 vs 54 (41, 70) years in sporadic insulinoma (p 
      = 0.04). There was no difference in sex or tumor size between MEN-1 and sporadic 
      malignant insulinoma (p > 0.05). Of the 260 patients with benign insulinoma, 
      7% had MEN-1 syndrome. MEN-1 patients presented with insulinoma at a younger age: 
      median (interquartile range) age was 38 (24, 49) years vs 52 (43, 65) years (p 
      < 0.01). Resection of benign insulinoma was performed in 78% of the MEN-1 and 
      94% of the sporadic group (p = 0.03). Resected benign tumors were larger in the 
      MEN-1 group: 2.0 (1.65, 2.45) cm vs 1.5 (1.2, 2.0) cm, respectively (p = 0.03). 
      Concurrent insulinomas were more common in MEN-1 (17% vs 2%; p < 0.01). 
      CONCLUSIONS: MEN-1 patients present with insulinoma at younger age and have 
      larger benign pancreatic lesions at the time of resection compared with sporadic 
      neoplasms. Younger patients and those with multifocal pancreatic neuroendocrine 
      tumor in the setting of endogenous hyperinsulinism should be evaluated for MEN-1.
CI  - Copyright (c) 2022 by the American College of Surgeons. Published by Wolters Kluwer 
      Health, Inc. All rights reserved.
FAU - Sada, Alaa
AU  - Sada A
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
FAU - Habermann, Elizabeth B
AU  - Habermann EB
AD  - Division of Health Care Delivery Research (Habermann), Mayo Clinic, Rochester, 
      MN.
FAU - Szabo Yamashita, Thomas
AU  - Szabo Yamashita T
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
FAU - Thompson, Geoffrey B
AU  - Thompson GB
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
FAU - Lyden, Melanie L
AU  - Lyden ML
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
FAU - Foster, Trenton R
AU  - Foster TR
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
FAU - Dy, Benzon M
AU  - Dy BM
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
FAU - Halfdanarson, Thorvardur R
AU  - Halfdanarson TR
AD  - Division of Medical Oncology (Halfdanarson), Mayo Clinic, Rochester, MN.
FAU - Vella, Adrian
AU  - Vella A
AD  - Division of Endocrinology (Vella), Mayo Clinic, Rochester, MN.
FAU - McKenzie, Travis J
AU  - McKenzie TJ
AD  - From the Department of Surgery (Sada, Szabo Yamashita, Thompson, Lyden, Foster, 
      Dy, McKenzie), Mayo Clinic, Rochester, MN.
LA  - eng
PT  - Journal Article
DEP - 20221017
PL  - United States
TA  - J Am Coll Surg
JT  - Journal of the American College of Surgeons
JID - 9431305
SB  - IM
MH  - Adult
MH  - Humans
MH  - *Insulinoma/diagnosis/epidemiology/surgery
MH  - *Multiple Endocrine Neoplasia Type 1/complications/diagnosis/genetics
MH  - *Pancreatic Neoplasms/diagnosis/epidemiology/etiology
MH  - Retrospective Studies
EDAT- 2022/06/26 06:00
MHDA- 2022/10/20 06:00
CRDT- 2022/06/25 23:52
PHST- 2022/06/26 06:00 [pubmed]
PHST- 2022/10/20 06:00 [medline]
PHST- 2022/06/25 23:52 [entrez]
AID - 00019464-202211000-00008 [pii]
AID - 10.1097/XCS.0000000000000307 [doi]
PST - ppublish
SO  - J Am Coll Surg. 2022 Nov 1;235(5):756-763. doi: 10.1097/XCS.0000000000000307. 
      Epub 2022 Oct 17.